[{"address1": "12730 High Bluff Drive", "address2": "Suite 400", "city": "San Diego", "state": "CA", "zip": "92130", "country": "United States", "phone": "858 500 8800", "website": "https://kuraoncology.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors. It has a clinical collaboration with Novartis Pharma AG to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma whose tumors have HRAS overexpression and/or PIK3CA mutation and/or amplification; and strategic collaboration agreement with Kyowa Kirin Co., Ltd. to develop and commercialize its oral menin inhibitor for the treatment of patients with acute myeloid leukemia (AML) and other hematologic malignancies. The company was founded in 2014 and is headquartered in San Diego, California.", "fullTimeEmployees": 142, "companyOfficers": [{"maxAge": 1, "name": "Dr. Troy Edward Wilson J.D., Ph.D.", "age": 55, "title": "Chairman, CEO & President", "yearBorn": 1969, "fiscalYear": 2023, "totalPay": 1216663, "exercisedValue": 0, "unexercisedValue": 2114416}, {"maxAge": 1, "name": "Ms. Kathleen  Ford", "age": 77, "title": "Chief Operating Officer", "yearBorn": 1947, "fiscalYear": 2023, "totalPay": 824946, "exercisedValue": 0, "unexercisedValue": 222965}, {"maxAge": 1, "name": "Ms. Teresa Brophy Bair Esq., J.D.", "age": 53, "title": "Chief Legal Officer & Corporate Secretary", "yearBorn": 1971, "fiscalYear": 2023, "totalPay": 705385, "exercisedValue": 0, "unexercisedValue": 69085}, {"maxAge": 1, "name": "Dr. Stephen  Dale M.D.", "age": 52, "title": "Chief Medical Officer", "yearBorn": 1972, "fiscalYear": 2023, "totalPay": 855297, "exercisedValue": 0, "unexercisedValue": 120877}, {"maxAge": 1, "name": "Mr. Thomas  Doyle", "age": 53, "title": "Senior Vice President of Finance & Accounting", "yearBorn": 1971, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Pete  De Spain", "title": "Executive Vice President of Investor Relations & Corporate Communications", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Roger  Bakale Ph.D.", "title": "Senior Vice President of Manufacturing & Supply Chain", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Maureen  Clancy M.B.A.", "title": "VP and Global Head of Program Leadership & Project Management", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Mollie  Leoni M.D.", "title": "Executive Vice President of Clinical Development", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Brian T. Powl M.B.A., M.S.", "age": 50, "title": "Chief Commercial Officer", "yearBorn": 1974, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 5, "boardRisk": 7, "compensationRisk": 6, "shareHolderRightsRisk": 8, "overallRisk": 7, "governanceEpochDate": 1735689600, "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 2, "previousClose": 8.71, "open": 8.78, "dayLow": 8.62, "dayHigh": 8.8697, "regularMarketPreviousClose": 8.71, "regularMarketOpen": 8.78, "regularMarketDayLow": 8.62, "regularMarketDayHigh": 8.8697, "beta": 0.857, "forwardPE": -4.539844, "volume": 1046184, "regularMarketVolume": 1046184, "averageVolume": 1615437, "averageVolume10days": 2068090, "averageDailyVolume10Day": 2068090, "bid": 8.66, "ask": 8.7, "bidSize": 1200, "askSize": 1200, "marketCap": 674989824, "fiftyTwoWeekLow": 8.42, "fiftyTwoWeekHigh": 24.17, "fiftyDayAverage": 13.3031, "twoHundredDayAverage": 18.52045, "currency": "USD", "enterpriseValue": 238654256, "floatShares": 50215164, "sharesOutstanding": 77763800, "sharesShort": 8888988, "sharesShortPriorMonth": 11034861, "sharesShortPreviousMonthDate": 1731628800, "dateShortInterest": 1734048000, "sharesPercentSharesOut": 0.114300005, "heldPercentInsiders": 0.01051, "heldPercentInstitutions": 1.1395401, "shortRatio": 3.32, "shortPercentOfFloat": 0.1154, "impliedSharesOutstanding": 77763800, "bookValue": 5.451, "priceToBook": 1.5923684, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1727654400, "netIncomeToCommon": -197552000, "trailingEps": -2.35, "forwardEps": -2.67, "enterpriseToEbitda": -1.102, "52WeekChange": -0.4427383, "SandP52WeekChange": 0.25443196, "exchange": "NMS", "quoteType": "EQUITY", "symbol": "KURA", "underlyingSymbol": "KURA", "shortName": "Kura Oncology, Inc.", "longName": "Kura Oncology, Inc.", "firstTradeDateEpochUtc": 1442410200, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EST", "uuid": "d959d119-9140-35ab-8205-a916e1fac9db", "messageBoardId": "finmb_282774456", "gmtOffSetMilliseconds": -18000000, "currentPrice": 8.68, "targetHighPrice": 37.0, "targetLowPrice": 11.0, "targetMeanPrice": 28.57143, "targetMedianPrice": 29.5, "recommendationKey": "none", "numberOfAnalystOpinions": 14, "totalCash": 455296992, "totalCashPerShare": 5.855, "ebitda": -216644000, "totalDebt": 16629000, "quickRatio": 11.394, "currentRatio": 11.473, "debtToEquity": 3.924, "returnOnAssets": -0.2854, "returnOnEquity": -0.46280998, "freeCashflow": -93215000, "operatingCashflow": -169122000, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2025-01-02"}]